title: Clear cell cancer of the uterine corpus: the association of clinicopathologic parameters and treatment on disease progression.
abstract: This paper presents a single-institution experience regarding the clinicopathologic features and treatment strategies used in uterine clear cell cancer (UCC), a rare, aggressive histologic subtype of uterine cancer with poor prognosis and discusses parameters associated with progression-free survival (PFS) and overall survival (OS). A retrospective chart review was performed on all patients (n = 80) diagnosed with UCC and treated between 1994 and 2009 at a single academic institution. Data on demographics, FIGO stage, treatment regimens, and recurrences were collected. Patients with early-stage UCC had an excellent survival regardless of adjuvant therapy. Advanced-stage patients had a worse survival. Vaginal apex brachytherapy was associated with an increased OS (P = 0.02) but not PFS (P = 0.10). The use of platinum-based chemotherapy in combination with vaginal apex brachytherapy did not significantly improve survival. Innovative therapies still need to be identified for this uncommon uterine cancer.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208063, New Haven, CT 06520, USA.
authors.forename: Joyce
authors.initials: J
authors.lastname: Varughese
authors.forename: Pei
authors.initials: P
authors.lastname: Hui
authors.forename: Lingeng
authors.initials: L
authors.lastname: Lu
authors.forename: Herbert
authors.initials: H
authors.lastname: Yu
authors.forename: Peter E
authors.initials: PE
authors.lastname: Schwartz